Newswise Feature Channel: Weight Loss

PCORI Awards $37 Million To Accelerate Implementation of Evidence-Based Health Research

Patient-Centered Outcomes Research Institute (PCORI) — Wed, 02 Oct 2024 11:05:44 EST

The Patient-Centered Outcomes Research Institute (PCORI) today announced $37 million in funding awards through its Health Systems Implementation Initiative (HSII). These awards will support 25 projects implementing PCORI-funded comparative clinical effectiveness research (CER) findings in participating HSII health systems.

Popular Diabetes and Weight-Loss Drug Associated with Lower Opioid Overdose Risk

Case Western Reserve University — Wed, 25 Sep 2024 11:00:00 EST

Case Western Reserve University School of Medicine identifies a potential new approach to address the opioid overdose epidemic--which has devastated families and communities nationally. Semaglutide was found to lower opioid overdoses in people with opioid-use disorder (OUD) and type 2 diabetes (T2D).

Mount Sinai Health System and Noom Partner to Help Patients Achieve Healthy Weight Loss Outcomes With an On-Demand Digital Health Platform

Mount Sinai Health System — Wed, 25 Sep 2024 08:00:48 EST

Mount Sinai Health System, a leading health system in the United States and one of the largest in the New York City area, and Noom, the leading digital health care company committed to chronic disease prevention and empowering people to live better and healthier lives, have partnered to provide patients with a whole-person approach to healthy, long-lasting weight loss.

Proteins Prohibitins Can Become New Targets for Drugs From Obesity

Scientific Project Lomonosov — Tue, 24 Sep 2024 07:05:28 EST

Scientists from Immanuel Kant Baltic Federal University analyzed scientific works dedicated to the role of proteins prohibitins in the development of obesity. It turned out that these proteins promote development of inflammation both in separate cells and the whole organism. This happens because prohibitins stimulate emission of anti-inflammatory substances by immune cells, and also participate in destruction of mitochondria damaged during oxidative stress. Obtained information points to the fact that prohibitins can become targets for medicine aimed at struggle with obesity consequences. Results of the research are published in the magazine Frontiers in Molecular Biosciences.

The Heart of the Question: Who Can Get Medicare-Covered Weight Loss Medicine?

Michigan Medicine - University of Michigan — Mon, 23 Sep 2024 17:30:26 EST

Wegovy (semaglutide) now has Medicare approval for coverage among people with obesity and cardiovascular disease but no diabetes; a study looks at what level of risk might make someone eligible.

American Society of Nephrology Releases Kidney Health Guidance on the Management of Obesity in Persons with Kidney Diseases

American Society of Nephrology (ASN) — Wed, 18 Sep 2024 12:00:00 EST

To promote high-quality, person-directed care across the spectrum of kidney health and diseases the American Society of Nephrology (ASN) is releasing its inaugural Kidney Health Guidance (KHG) on the Management of Obesity in Persons Living with Kidney Diseases in the Journal of the American Society of Nephrology (JASN) on September 18, 2024.

Endurance Exercise without Weight Loss May Reduce Body Fat

American Physiological Society (APS) — Wed, 18 Sep 2024 07:00:17 EST

Participating in a high volume of exercise over a short period of time, such as cycling hundreds of miles in a few days, could reduce body fat levels without weight loss. The first-of-its-kind study is published ahead of print in the American Journal of Physiology-Endocrinology and Metabolism and has been chosen as an APSselect article for September.

Research Assesses Impact of Weight Loss and Blood Sugar Control in Type 2 Diabetes

Cleveland Clinic — Tue, 17 Sep 2024 09:05:48 EST

Survey Shows 25% of Adults Consider Weight Loss Drug Use Without Prescription

Ohio State University Wexner Medical Center — Tue, 17 Sep 2024 00:05:00 EST

A new national survey from The Ohio State University Wexner Medical Center reveals 1 in 4 (25%) of 1,006 adults surveyed would consider using an injectable weight loss medication without consulting their doctor.

Cleveland Clinic Study Identifies Key Factors That Can Impact Long-Term Weight Loss in Patients with Obesity Who Were Prescribed GLP-1 RA Medications

Cleveland Clinic — Fri, 13 Sep 2024 11:00:00 EST

Cleveland Clinic Study Identifies Key Factors That Can Impact Long-Term Weight Loss in Patients with Obesity Who Were Prescribed GLP-1 RA Medications

Penn study finds taking semaglutide for weight management does not increase risk of depression or suicidal behavior in people without known major psychopathology

Perelman School of Medicine at the University of Pennsylvania — Tue, 03 Sep 2024 11:00:00 EST

Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal Medicine. Both the Food and Drug Administration (FDA) and the European Medicines Agency are actively monitoring the psychiatric safety of semaglutide and similar medications after post marketing surveillance reports of depression, suicidal thoughts (ideation), and suicidal behavior in patients taking the drugs for the management of type 2 diabetes or obesity.

Nutrition know-how for patients taking anti-obesity medication

UT Southwestern Medical Center — Thu, 29 Aug 2024 13:05:40 EST

Since anti-obesity medications have become more widely known and prescribed, they have been touted as game-changing treatments for chronic overweight and obesity. But one common misconception about these medications is that they're a magic bullet for better health, and it doesn't necessarily matter what you eat when you're taking them.

Primary Care Providers Urged to Assist Patients Who Engage in Emotional Eating

Wolters Kluwer Health: Lippincott — Wed, 28 Aug 2024 12:30:53 EST

Primary care providers are well positioned to address emotional eating because of their long-term relationships with patients, noted Jana DeSimone Wozniak, PhD and Hsiang Huang, MD, MPH, of Harvard Medical School and Cambridge Health Alliance in Cambridge, Massachusetts.

High BMI eligibility for semaglutide could cost Medicare an additional $145 billion annually

American College of Physicians (ACP) — Mon, 26 Aug 2024 17:00:00 EST

A brief research report found that 61% of Medicare-eligible adults have a BMI of 27 or higher, which means they may benefit from a GLP-1 receptor agonist like semaglutide for weight loss.

Five Common Myths About Weight Loss

University of Utah Health — Mon, 26 Aug 2024 15:05:16 EST

Popular ideas about weight loss often aren't based in science and can actively harm your health. Here are some of the most common myths, along with some tips to improve your health sustainably while maintaining a healthy attitude toward weight and food.

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Palatin Technologies, Inc. — Thu, 22 Aug 2024 07:05:30 EST

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity (ClinicalTrials.gov Identifier: NCT06565611).

How do GLP-1 weight loss drugs affect the liver?

Michigan Medicine - University of Michigan — Tue, 20 Aug 2024 10:30:10 EST

Drugs such as Ozempic, Rybelsus and Wegovy have made news for their abilities to treat diabetes and encourage weight loss. To give a clearer understanding of the benefits and risks of GLP-1 agonists for patients with liver disease, Robert Fontana, M.D., a Michigan Medicine hepatologist, answered our questions.

Combining Two Diabetes Drugs Helps Promote Weight Loss and Blood Sugar Control

American Physiological Society (APS) — Tue, 20 Aug 2024 07:00:25 EST

New research finds a combination of drugs improves weight loss, glucose control and insulin resistance better than either drug alone. Using two diabetes medications together, such as a semaglutide like Ozempic or Rybelsus, with a second, newer class of drug, may offer a noninvasive solution to help people with Type 2 diabetes lose weight and manage their condition without the need for bariatric surgery.

One Size Does Not Fit All

Cedars-Sinai — Wed, 07 Aug 2024 10:05:54 EST

A new class of medications called GLP-1s (glucagon-like peptide-1 receptor agonists) have been grabbing headlines for their dramatic results in helping people shed stubborn pounds, thereby controlling diabetes as well as reducing their risk of heart disease.

Navigating a weight loss journey

Michigan Medicine - University of Michigan — Mon, 05 Aug 2024 16:05:34 EST

One patient details her success story losing weight through this individualized approach